State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 12,294,412 shares of BioCryst Pharmaceuticals Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 12,294,412 shares of BioCryst Pharmaceuticals Inc common stock.
  • Percent of class: The disclosed stake represents 4.8% of the outstanding class of common stock, according to the filing.
  • Shared voting power: State Street reported shared voting power over 11,692,962 shares, with sole voting power of 0.
  • Shared dispositive power: The filing shows shared dispositive power over 12,294,412 shares, with sole dispositive power of 0.
  • Triggering event date: The date of the event requiring the filing is listed as September 30, 2026.
  • Subsidiaries involved: The filing identifies five investment adviser subsidiaries as the entities through which the shares were acquired, including SSGA Funds Management, Inc. and State Street Global Advisors Europe Limited, among others.
  • Ordinary course certification: State Street certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

State Street Corporation Discloses Sub-5% Position in BioCryst via 13G

State Street Corporation, a holding company organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in BioCryst Pharmaceuticals Inc (CUSIP 09058V103). BioCryst Pharmaceuticals Inc is headquartered at 4505 Emperor Blvd Suite 200, Durham, North Carolina 27703, according to the filing. The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026.

According to the filing, State Street's aggregate beneficial ownership stands at 12,294,412 shares, representing 4.8% of the class. The company reported no sole voting or dispositive power; all reported voting authority (11,692,962 shares) and all dispositive authority (12,294,412 shares) are shared. Item 5 of the filing notes ownership of 5 percent or less of the class. The filing identifies State Street as a parent holding company (type "HC") filing under the Schedule 13G framework.

Five subsidiaries are identified in Item 7 as the entities that acquired the securities on behalf of the parent: SSGA Funds Management, Inc. (IA); State Street Global Advisors Europe Limited (IA); State Street Global Advisors Limited (IA); State Street Global Advisors Trust Company (IA); and State Street Global Advisors, Ltd. (IA). Each is classified as an investment adviser. The filing indicates Item 6 (ownership of more than 5 percent on behalf of another person) and Item 8 (group membership) are not applicable.

What Was Disclosed

State Street Corporation disclosed a 4.8% beneficial ownership position, totaling 12,294,412 shares of BioCryst Pharmaceuticals Inc common stock, held through five investment adviser subsidiaries as of September 30, 2026, with all voting and dispositive power held on a shared basis.